Contact
Please use this form to send email to PR contact of this press release:
LATITUDE Pharmaceuticals Develops an SC/IM Injectable Remdesivir Formulation
TO:
Matthew A. Singer, PhD
LATITUDE Pharmaceuticals Inc.
+1 858-342-2065